HIP Fracture Accelerated Surgical TreaTment and Care TracK 2 Trial

Description

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

Conditions

Hip Fractures, Myocardial Injury

Talk to us

Study Overview

On this page

Study Details

Study overview

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

HIP Fracture Accelerated Surgical TreaTment and Care TracK 2 (HIP ATTACK-2) Trial

HIP Fracture Accelerated Surgical TreaTment and Care TracK 2 Trial

Condition
Hip Fractures
Intervention / Treatment

-

Contacts and Locations

Davis

The Regents of the University of California, Davis, California, United States, 95618

Baltimore

University of Maryland, Baltimore, Maryland, United States, 20742

Burlington

Lahey Hospital and Medical Center, Burlington, Massachusetts, United States, 01805

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Lincoln

Bryan Medical Center, Lincoln, Nebraska, United States, 68506

Bronx

Montefiore Medical Center, Bronx, New York, United States, 10467

Cleveland

Cleveland Clinic, Cleveland, Ohio, United States, 44195

Madison

University of Wisconsin, Madison, Wisconsin, United States, 53715

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. age ≥45 years;
  • 2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery;
  • 3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and
  • 4. informed consent.
  • 1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe;
  • 2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT);
  • 3. patients with peri-prosthetic fracture, open fracture or bilateral fractures;
  • 4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma);
  • 5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock;
  • 6. patients refusing consent; or
  • 7. patients previously enrolled in HIP ATTACK-2.

Ages Eligible for Study

45 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Population Health Research Institute,

Flavia Borges, M.D, PRINCIPAL_INVESTIGATOR, Population Health Research Institute

Gerard Slobogean, M.D, PRINCIPAL_INVESTIGATOR, University of Maryland, Baltimore

Robert Feibel, M.D, PRINCIPAL_INVESTIGATOR, The Ottawa Hospital

PJ Devereaux, M.D, STUDY_CHAIR, Population Health Research Institute

Study Record Dates

2027-05-31